A VS BIIB Stock Comparison

Performance

A
29/100

A returned -20.34% in the last 12 months. Based on SPY's performance of -16.79%, its performance is below average giving it a score of 28 of 100.

BIIB
74/100

BIIB returned -15.64% in the last 12 months. Based on SPY's performance of -20.65%, its performance is above average giving it a score of 74 of 100.

Analyst Price Targets

A
82/100

14 analysts offer 12-month price targets for A. Together, they have an average target of 167.75, the most optimistic target put A at 170 within 12-months and the most pessimistic has A at 161.

BIIB
73/100

32 analysts offer 12-month price targets for BIIB. Together, they have an average target of 294.73, the most optimistic target put BIIB at 405 within 12-months and the most pessimistic has BIIB at 209.

Sentiment

A
69/100

A had a bullish sentiment score of 69.50% across Twitter and StockTwits over the last 12 months. It had an average of 77.66 posts, 409.66 comments, and 1,364.19 likes per day.

BIIB
70/100

BIIB had a bullish sentiment score of 70.25% across Twitter and StockTwits over the last 12 months. It had an average of 66.53 posts, 492.48 comments, and 835.41 likes per day.

Technicals

A
50/100

A receives a 50 of 100 based on 14 indicators. 6 are bullish, 6 are bearish.

BIIB
14/100

BIIB receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.

Earnings

A
100/100

A has missed earnings 0 times in the last 20 quarters.

BIIB
61/100

BIIB has missed earnings 2 times in the last 20 quarters.

Profit

A
79/100

Out of the last 20 quarters, A has had 20 profitable quarters and has increased their profits year over year on 10 of them.

BIIB
64/100

Out of the last 20 quarters, BIIB has had 19 profitable quarters and has increased their profits year over year on 6 of them.

Volatility

A
52/100

A has had a higher than average amount of volatility over the last 12 months giving it a score of 51 of 100.

BIIB
40/100

BIIB has had a lower than average amount of volatility over the last 12 months giving it a score of 40 of 100.

Dividend

A
48/100

A's most recent dividend was $0.15 per share, based on a share price of $109.02. It was a payout ratio of 24.10% compared to their total earnings.

BIIB

"Dividend" not found for BIIB

All score calculations are broken down here to help you make more informed investing decisions

Agilent Technologies Inc. Summary

New York Stock Exchange / A

Healthcare

Medical - Diagnostics & Research

Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps, and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, gene expression profiling, next generation sequencing, target enrichment and genetic data management, and interpretation support software; and produces synthesized oligonucleotide. It also offers immunohistochemistry in situ hybridization, and hematoxylin and eosin staining and special staining; consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops liquid-based pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.

Biogen Inc. Common Stock Summary

Nasdaq / BIIB

Healthcare

Drug Manufacturers - General

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Power up your portfolio